Skip to main content
SpringerLink
Log in

Ergot Alkaloids

Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared with Other Oxytocics in Obstetrics and Gynaecology

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ergot alkaloids are well known preparations. Ergot alkaloids used in obstetrics and gynaecology are ergometrine (ergonovine; EM), methylergometrine (methergine; ME) and bromocriptine. The pharmaceutical properties of ME EM) are critical. To guarantee stability, ME and EM ampoules should be stored in a cool, dark place. ME and EM tablets are unstable in all conditions and they show an unpredictable bioavailability, which prevents oral use of the drugs for any purpose.

ME and EM are known for their strong uterotonic effect and, compared with other ergot alkaloids, for their relatively slight vasoconstrictive abilities. ME and EM do have a place in the management of the third stage of labour as they are strong uterotonics. They act differently from oxytocin and prostaglandins, and have different adverse effects. Oxytocin should be used as prophylaxis or a the drug of first choice; next, ME or EM should be used, and if none of these drugs produce the desired effects, prostaglandins should be used to control bleeding.

Ergot alkaloid use in gynaecology has been limited and today is discouraged even in essential menorrhagia. It is suggested that EM and ME be used (parenterally) only in first trimester abortion curettage, to reduce blood loss. Bromocriptine has been used for lactation suppression. However, alternatives such as cabergoline, which possess fewer adverse effects, are now available and therefore preferred for this indication.

In sum, there is no place for the prophylactic use of ME and EM in obstetrics or gynaecology. They can be used for therapeutic purposes in the third stage of labour. During use, the practitioner must be alert for adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clark BJ. The versatile ergot of rye. In: Parnham MJ, Bruinvels J, editors. Discoveries in pharmacology. Vol. 2: haemodynamics, hormones and inflammation. Amsterdam: Elsevier Science Publishers BV, 1984: 3–33

    Google Scholar 

  2. Crijns M, van Leeuwen R. Huidziekten in de beeidende kust [Dermatology in art]. ’s-Hertogenbosch: Glaxo BV, 1992: 34–7

  3. van Dongen PWJ, de Groot ANJA. History of ergot alkaloids: from ergotism to ergometrine. Eur J Obstet Gynecol Reprod Biol 1995; 60: 109–16

    Article  PubMed  Google Scholar 

  4. Barger G. Ergot and ergotism: a monograph. In: Gurney, Jackson, editors. London-Edinburgh, 1931

  5. Hosack D. Observations on ergot no. 19. In: Essays on various subjects of medical science, New York [letter, dated June 2, 1822, to James Hamilton, Edinburgh] 1824; 2: 295–301

    Google Scholar 

  6. Tanret C. Sur la présence d’un nouvel alkaloide, l’ergotinine, dans le seigle ergoté. CR Acad Sci 1875; 81: 896–7

    Google Scholar 

  7. Moir JC. Ergot: from ‘St Anthony’s Fire’ to the isolation of its active principle, ergometrine (Ergonovine). Am J Obstet Gynecol 1974; 120: 291–6

    PubMed  CAS  Google Scholar 

  8. de Groot ANJA. The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol 1996; 69: 31–6

    Article  PubMed  Google Scholar 

  9. Rolland R. Use of bromocriptine in the inhibition of puerperal lactation. Drugs 1979; 17: 326–36

    Article  PubMed  CAS  Google Scholar 

  10. van Eijkeren MA, Christiaens GC, Scholten PC. Menorrhagia: current drug treatment concepts. Drugs 1992; 43(2): 201–9

    Article  PubMed  Google Scholar 

  11. Nilsson S, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971; 110: 713–20

    PubMed  CAS  Google Scholar 

  12. Rall TW. Drug affecting uterine motility: oxytocin, prostaglandins, ergot alkaloids and other drugs. Tocolytic agents. In: Goodman AN, Gilman A, Rail TW, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. MacMillan: New York, 1990: 933–53

    Google Scholar 

  13. Glover DD, Halki JJ. Ergonovine, methylergonovine. In: Halperin JA, editor. USPDI: Drug information for the health professional. United States Pharmacopoeial Convention. 11th ed. Vol. IA. Rockville (MD): US Pharmacopoeial Convention Inc, 1991: 1244–7, 1788–91

    Google Scholar 

  14. Rutschmann J, Stadler PA. Chemical background. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978: 29–85 (Handbook of experimental pharmacology; 49)

    Chapter  Google Scholar 

  15. Müller-Schweinitzer E, Weidemannn H. Basic pharmacological properties. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978: 87–196 (Handbook of experimental pharmacology; 49)

    Chapter  Google Scholar 

  16. Berde B, Stürmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978: 1–28 (Handbook of experimental pharmacology; 49)

    Chapter  Google Scholar 

  17. Leist KH, Grauwiler J. Ergometrine and uteroplacental blood supply in pregnant rats [letter]. Teratology 1974; 10: 316

    Article  Google Scholar 

  18. van Dongen PWJ, van Roosmalen J, de Boer CN, et al. Oxytocics for the prevention of postpartum haemorrhages [review]. Pharm Weekbl Sci 1991; 13(6): 238–43

    Article  PubMed  Google Scholar 

  19. Forman A, Gandrup P, Andersson K, et al. Effects of nifedipine on spontaneous and methylergometrine-induced activity postpartum. Am J Obstet Gynecol 1982; 144(4): 442–7

    PubMed  CAS  Google Scholar 

  20. Cibils LA, Hendricks CH. Effect of ergot derivates and sparteine sulfate upon the human uterus. J Reprod Med 1969; 2: 147–67

    Google Scholar 

  21. Daels J. Uterine contractility patterns of the outer and inner zones of the myometrium. Obstet Gynecol 1974; 44: 315–26

    PubMed  CAS  Google Scholar 

  22. de Koning Gans HJ, Martinez AAV, Eskes TKAB. Intermittent low-dose administration of prostaglandins intraamniotically in pathological pregnancies: a comparison with oxytocin and ergometrine. Eur J Obstet Gynecol Reprod Biol 1975; 5/6: 307–15

    Article  Google Scholar 

  23. Saameli K. Effects on the uterus. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Berlin: Springer Verlag, 1978: 233–319 (Handbook of experimental pharmacology; 49)

    Chapter  Google Scholar 

  24. Hendricks CH. Uterine contractility changes in the early puerperium. Clin Obstet Gynecol 1968; 11: 125–44

    Article  PubMed  CAS  Google Scholar 

  25. Walker GJA, Hogerzeil HV, Lindgren U. Potency of ergometrine in tropical countries [letter]. Lancet 1988; II: 393

    Article  Google Scholar 

  26. Hogerzeil HV, Walker GJA, de Goeje MJ. Oxytocin more stable in tropical climates [letter]. BMJ 1994; 308: 59

    PubMed  CAS  Google Scholar 

  27. Hogerzeil HV, Walker GJA. Instability of (methyl)ergometrine in tropical climates: an overview. Eur J Obstet Gynecol Reprod Biol 1996; 69: 25–9

    Article  PubMed  CAS  Google Scholar 

  28. de Groot ANJA, Hekster YA, Vree TB, et al. Ergometrine and methylergometrine tablets are not stable under simulated tropical conditions. J Clin Pharm Ther 1995; 20: 109–13

    Article  PubMed  Google Scholar 

  29. Hogerzeil HV, Walker GJA, De Goeije MJ. Stability of injectable oxytocics in tropical climates. Geneva: World Health Organization, 1993: WHO/DAP/93.6

    Google Scholar 

  30. de Groot ANJA, Vree TB, Hogerzeil HV, et al. Stability of oral oxytocics in tropical climates. Geneva: World Health Organization, 1994: WHO/DAP/94.13

    Google Scholar 

  31. El-Refaey H, O’Brien P, Morafa W, et al. Use of oral misoprostol in the prevention of postpartum haemorrhage. Br J Obstet Gynaecol 1997; 104: 336–9

    Article  PubMed  CAS  Google Scholar 

  32. Hogerzeil HV, Walker GJA, Van de Langerijt AEEM. The colour of ergometrine: how to recognize low level of active ingredient. Trop Doct 1994; 24: 112–4

    PubMed  CAS  Google Scholar 

  33. Mantyla R, Kleimol T, Kanto J. Methylergometrine concentrations in the human plasma and urine. Int J Clin Pharmacol 1978; 16: 254–7

    CAS  Google Scholar 

  34. de Groot ANJA, Vree TB, Hekster YA, et al. Comparison of bioavailability and pharmacokinetics of oral methylergometrine in men and women. Int J Clin Pharm Ther 1995; 33: 328–32

    Google Scholar 

  35. de Groot ANJA, Vree TB, Hekster YA, et al. Pharmacokinetics and bioavailability of oral ergometrine in male volunteers. Biopharm Drug Dispos 1994; 15: 65–73

    Article  PubMed  Google Scholar 

  36. Anonymous. Ergot alkaloids and derivatives. In: Reynolds JF, editor. Martindale: the extra pharmacopoeia. 28th ed. London: Pharmaceutical Press, 1988: 1051–9

  37. Moir C, Dale HH. The action of ergot preparations on the puerperal uterus. BMJ 1932; 1: 1119–22

    Article  PubMed  CAS  Google Scholar 

  38. Dudley HW, Moir C. The substance responsible for the traditional clinical effect of ergot. BMJ 1935; 1: 520–3

    Article  PubMed  CAS  Google Scholar 

  39. Hendricks CH, Eskes TKAB, Saameli K. Uterine contractility at delivery and in the puerperium. Am J Obstet Gynecol 1962; 83: 890–907

    PubMed  CAS  Google Scholar 

  40. Fröhlich H. Steuermechanismen der Motilität des nichtgraviden Uterus in situ [Controlling mechanisms of contractility in non-pregnant uterus in vivo]. Wien Klin Wochenschr 1974; 86: S24: 3–28

    Google Scholar 

  41. de Groot ANJA, van Dongen PWJ, Vree TB, et al. Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant menstruating uterus. Eur J Obstet Gynecol Reprod Biol 1995; 60: 101–7

    Article  PubMed  Google Scholar 

  42. Fuchs AR, Fuchs F. Endocrinology of human parturition: a review. Br J Obstet Gynaecol 1984; 91: 948–67

    Article  PubMed  CAS  Google Scholar 

  43. Hayashi RH. The role of prostaglandins in the treatment of postpartum haemorrhage. J Obstet Gynecol 1990; S2: S21–4

    Google Scholar 

  44. Poeschmann RP, Doesburg WH, Eskes TKAB. A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. Br J Obstet Gynaecol 1991; 98: 528–30

    Article  PubMed  CAS  Google Scholar 

  45. Van Selm M, Kanhai HHH, Keirse MJNC. Preventing the recurrence of atonic postpartum hemorrhage: a double-blind trial. Acta Obstet Gynecol Scand 1995; 74: 270–4

    Article  PubMed  Google Scholar 

  46. Izumi H, Garfield RE, Morishita F, et al. Some mechanical properties of skinned fibres of pregnant myometrium. Eur J Obstet Gynecol Reprod Biol 1994; 56: 55–62

    Article  PubMed  CAS  Google Scholar 

  47. Takagi S, Yoshida T, Togo Y, et al. The effects of intramyometrial injection of prostaglandin F2a on severe postpartum hemorrhage. Prostaglandins 1976; 12(4): 565–77

    Article  PubMed  CAS  Google Scholar 

  48. de Groot ANJA, van Dongen PWJ, van Roosmalen J, et al. Ergotamine-induced fetal stress: case report and review of side effects of ergot alkaloids during pregnancy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 73–7

    Article  PubMed  Google Scholar 

  49. Prendiville WJ, Elbourne DR, Chalmers I. The effects of routine oxytocic administration in the management of the third stage of labour: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1988; 95: 3–16

    Article  PubMed  CAS  Google Scholar 

  50. Prendiville WJ. The prevention of post partum haemorrhage: optimising routine management of the third stage of labour. Eur J Obstet Gynecol Reprod Biol; 1996; 69: 19–24

    Article  PubMed  CAS  Google Scholar 

  51. McDonald SJ, Prendiville WJ, Blair E. Randomised controlled trial of oxytocin alone versus oxytocin and ergometrine in active management of the third stage of labour. BMJ 1993; 307: 1167–71

    Article  PubMed  CAS  Google Scholar 

  52. Begley CM. A comparison of ‘active’ and physiological management of the third stage of labour. Midwifery 1990; 6: 3–17

    Article  PubMed  CAS  Google Scholar 

  53. de Groot ANJA. Prevention of postpartum haemorrhage. In: Steegers EAP, Eskes TKAB, Symonds EM, editors. Clinical obstetrics and gynaecology, international practice and research: preventive care in obstetrics. London: Baillière Tindall, 1995: 619–31

    Google Scholar 

  54. Ringrose LAD. The obstetrical use of ergot: a violation of the doctrine ‘primum non nocere’. Can Med Assoc J 1962; 87: 712–4

    PubMed  CAS  Google Scholar 

  55. Spaulding C, Weber S, Guerin F. Coronary artery spasm triggered by oral administration of methylergometrine [letter]. Lancet 1991; 338: 317

    Article  PubMed  CAS  Google Scholar 

  56. Oneglia C, Marchetti A, Rusconi C. Methylergometrine induced myocardial ischemia in a previously asymptomatic premeno-pausal woman. Cardiovasc Drugs Ther 1995; 9: 631–2

    Article  PubMed  CAS  Google Scholar 

  57. Raymond GV. Teratogen update: ergot and ergotamine. Teratology 1995; 51: 344–7

    Article  PubMed  CAS  Google Scholar 

  58. Hendricks CH, Brenner WE. Cardiovascular effect of oxytocin drugs used postpartum. Am J Obstet Gynecol 1970; 108: 751–60

    PubMed  CAS  Google Scholar 

  59. Johnstone M. The cardiovascular effects of oxytocic drugs. Br J Anaesth 1972; 44: 826–33

    Article  PubMed  CAS  Google Scholar 

  60. Oxytocin [editorial]. In: Reynolds JF, editor. Martindale: the extra pharmacopoeia. 28th ed. London: Pharmaceutical Press, 1988: 1272–5

  61. Kilpatrick AWA, Thorburn J. Severe hypotension due to intramyometrial injection of prostaglandin E2. Anaesthesia 1990; 43: 848–9

    Article  Google Scholar 

  62. Fruzzetti F, Melis GB, Strigini F, et al. Use of sulprostone for induction of preoperative cervical dilation or uterine evacuation: a comparison among the effects of different treatment schedules. Obstet Gynecol 1988; 72: 704–8

    PubMed  CAS  Google Scholar 

  63. Fliers E, Düren DR, van Zwieten PA. A prostaglandin analogue as probable cause of myocardial infarction in a young woman [letter]. BMJ 1991; 301: 416

    Article  Google Scholar 

  64. A death associated with mifepristone/sulprostone [editorial]. Lancet 1991; 337: 969–70

  65. Ulmann A, Silvestre L. RU 486: the French experience. Hum Reprod 1994; 9: 126–30

    Article  PubMed  Google Scholar 

  66. El-Refaey H, Templeton A. Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and effect on blood pressure. Br J Obstet Gynaecol 1994; 101: 792–6

    Article  PubMed  CAS  Google Scholar 

  67. Jouppila P. Postpartum haemorrhage. Curr Opin Obstet Gynecol 1995; 7(6): 446–50

    Article  PubMed  CAS  Google Scholar 

  68. Yuen PM, Chan NST, Yim SF, et al. A randomized double blind comparison of syntometrine and syntocinon in the management of the third stage of labour. Br J Obstet Gynaecol 1995; 102: 377–80

    Article  PubMed  CAS  Google Scholar 

  69. Chou MM, MacKenzie IZ. A prospective, double-blind, randomized comparison of prophylactic intramyometrial 15-methyl-prostaglandin F2a, 125 micrograms, and intravenous oxytocin 20 units, for the control of blood loss at elective cesarean section. Am J Obstet Gynecol 1994; 171: 1356–60

    PubMed  CAS  Google Scholar 

  70. Beerendonk CCM, Massuger LFAG, Lucassen AMJ, et al. Circulatiestilstand na gebruik van sulproston bij fluxus post partum [Loss of circulation at administration of sulprostone because of haemorrhagia postpartum]. Ned Tijdschr Geneeskd 1998; 142: 195–7

    PubMed  CAS  Google Scholar 

  71. Micromedex Inc. Sulprostone: 3.0. Cautions. Drug evaluation monographs 1997: 94

  72. Alvarez M, Lockwood CJ, Ghidini A, et al. Prophylactic and emergent arterial catheterization for selective embolization in obstetric hemorrhage [letter]. Am J Perinatol 1992; 9: 441

    Article  PubMed  CAS  Google Scholar 

  73. B-Lynch C, Coker A, Lawas AH, et al. The B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. Br J Obstet Gynaecol 1997; 104: 372–5

    Article  PubMed  CAS  Google Scholar 

  74. Bromocriptine (Parlodel®) not for lactation suppression. [Bromocriptine (Parlodel®) niet voor lactatieremming]. GebuPrikbord 1994; 28(10): 84–5

    Google Scholar 

  75. McCarthy M. Bromocriptine not for lactation suppression [letter]. Lancet 1994; 344: 602

    Article  Google Scholar 

  76. Carcey J, Rosencher N, Guillaume F. Blood loss and nausea during legal abortion [Saignement et nausées lors d’interruptions volontaires de grossesse]. Ann Fr Anesth Reanim 1985; 4(3): 271–3

    Article  PubMed  CAS  Google Scholar 

  77. Ali PB, Smith G. The effect of syntocinon on blood loss during first trimester suction curettage. Anaesthesia 1996; 51(5): 483–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, University Hospital Nijmegen St Radboud, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

    Akosua N. J. A. de Groot & Pieter W. J. van Dongen

  2. Institute of Anaesthesiology, University Hospital Nijmegen St Radboud, Nijmegen, The Netherlands

    Tom B. Vree

  3. Department of Clinical Pharmacy, University Hospital Nijmegen St Radboud, Nijmegen, The Netherlands

    Yechiel A. Hekster

  4. Department of Obstetrics and Gynaecology, University Hospital Leiden, Leiden, The Netherlands

    Jos van Roosmalen

Authors
  1. Akosua N. J. A. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieter W. J. van Dongen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tom B. Vree
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yechiel A. Hekster
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jos van Roosmalen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Groot, A.N.J.A., van Dongen, P.W.J., Vree, T.B. et al. Ergot Alkaloids. Drugs 56, 523–535 (1998). https://doi.org/10.2165/00003495-199856040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199856040-00002

Keywords

Search

Navigation